AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
hVIVO plc
Video analysis: OPORF
All videosNo video analysis for this stock yet. Request one from our team.
News: OPORF
hVIVO buys Berlin trials unit for token upfront sum
hVIVO PLC (AIM:HVO), the clinical trials group, has bought a Berlin clinical research unit for an initial payment of just €250,000, with almost all of the price contingent on future revenue. The company said on Thursday it had acquired the entire share capital of CRS Clinical Research Services Berlin, a specialist site running early-stage studies in dermatology and women's Instead of a fixed price, hVIVO will pay 18% of the Berlin unit's annual revenue for each of the next three years, provided minimum revenue thresholds are met.
hVIVO CEO sees strong H2 2026 revenue outlook as development platform expands - ICYMI
This week hVIVO PLC (AIM:HVO) chief executive Mo Khan joined Proactive to talk about how the clinical research company has more than doubled its order book as commercial momentum accelerates. Khan said the company has transformed into an integrated end-to-end clinical development provider, with growing demand reflected in a 45% year-on-year increase in inbound client proposals.
hVIVO tipped for upside as order book 'more than doubles'
The reveal that hVIVO Plc's (AIM:HVO) order book has more than doubled to £65 million, prompting Shore Capital to reiterate a Buy rating and 25p target price despite a steep second-half delivery challenge. The target implies 270% upside from the current 6.8p share price.
hVIVO orderbook more than doubles to £65m as revenue shifts to second half
hVIVO PLC (AIM:HVO), the clinical trials specialist and world leader in human challenge studies, said its order book had more than doubled to £65 million since the start of the year. That compares with £30 million at the beginning of 2026 and gives the company far greater visibility over contracted revenues into 2027 and 2028.
